Breaking Finance News

Deutsche Bank disclosed BTG PLC (LON:BTG), supporting its price target at 775.00GBX earlier today

Boasting a price of 678.75GBX, BTG PLC (LON:BTG) traded -0.21% lower on the day. With the last stock price close up 5.80% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.03% over the same time. The company has recorded a 50-day moving average of 686.88GBX and a 200-day moving average of 667.32GBX. 23,274 shares of BTG traded hands, down from an average trading volume of 476,147

Reporting a potential upside of 0.14%, Deutsche Bank hold steady the price target of BTG PLC (LON:BTG) at 775.00GBX

On 10/06/2017, Deutsche Bank released a statement about BTG PLC (LON:BTG) maintained the target price at 775.00GBX that suggested an upside of 0.14%.

Recent Performance Chart


BTG PLC has 52 week low of 528.36GBX and a 52 week high of 738.50GBX with a PE ratio of 82.09 and has a market capitalization of 0 GBX.

Brief Synopsis On BTG PLC (LON:BTG)

BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing. The Interventional Medicine segment includes oncology, vascular and pulmonology. The segment's products include Beads, TheraSphere, EkoSonic, Varithena and PneumRx Coils for use in the treatment of liver tumors, blood clots, varicose veins and advanced emphysema. The Specialty Pharmaceuticals segment includes CroFab, DigiFab, Voraxaze and Vistogard products for use in the treatment of crotalid envenomation, digoxin toxicity, high-dose methotrexate toxicity and 5-fluorouracil toxicity. The Licensing segment includes Zytiga, Two-Part Hip Cup and Lemtrada products for use in the treatment of advanced prostate cancer, hip replacement and multiple sclerosis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.